Valuation: Sutro Biopharma, Inc.

Market Cap 155M 138M 128M 116M 216M 14.69B 220M 1.54B 608M 7.69B 581M 568M 24.26B P/E 2026 *
-1.13x
P/E 2027 * -1.41x
Enterprise Value 155M 138M 128M 116M 216M 14.69B 220M 1.54B 608M 7.69B 581M 568M 24.26B EV / Sales 2026 *
3x
EV / Sales 2027 * 4.9x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-9.33%
1 week-14.72%
Current month-42.09%
1 month-40.69%
3 months-60.47%
6 months-73.21%
Current year-19.36%
1 week 9.16
Extreme 9.16
11.8
1 month 9.16
Extreme 9.16
16.66
Current year 9.16
Extreme 9.16
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 2025-03-12
Director of Finance/CFO 53 2025-06-01
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 70 2009-07-31
Director/Board Member 67 2017-01-31
Director/Board Member 51 2018-07-24
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Exercice

Chief Technology Officer

8,845 0.0533%
6/2/26 Exercice

Chief Financial Officer

5,000 0.0302%
3/4/26 Exercice

Chief Administrative Officer

1,627 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-9.33%-14.72%-11.98%-68.37% 155M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.69%+0.70%+43.36%+134.96% 38.33B
Weighted average by Cap. +0.39%+2.72%+47.55%+158.48%

Financials

2026 *2027 *
Net sales 51.55M 46.03M 42.53M 38.54M 72.1M 4.89B 73.29M 512M 203M 2.56B 193M 189M 8.08B 31.6M 28.21M 26.06M 23.62M 44.19M 3B 44.92M 314M 124M 1.57B 119M 116M 4.95B
Net income -130M -116M -107M -96.83M -181M -12.29B -184M -1.29B -509M -6.44B -486M -476M -20.31B -141M -126M -116M -105M -197M -13.36B -200M -1.4B -553M -7B -528M -517M -22.07B
Net Debt - -
Projected Income Statement - Annual - Sutro Biopharma, Inc.
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
26-10-23 US$9.330 -9.33% 430,837
26-10-22 US$10.29 -4.63% 293,292
26-10-21 US$10.79 -6.50% 439,854
26-10-20 US$11.54 +2.53% 273,807
26-10-19 US$11.26 +2.88% 345,147
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Sutro Biopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
9.330USD
Average target price
47.23USD
Spread / Average Target
+406.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sutro Biopharma, Inc.
  1. Stock Market
  2. Stocks
  3. STRO Stock